Immunotherapy for myasthenia gravis: A murine model

P. Christadoss, M. J. Dauphinee

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

In vivo therapy with monoclonal antibody (mAb) GK1.5, which recognizes a glycoprotein antigen designated L3T4 on murine helper T lymphocytes, either prevented or suppressed the development of murine lupus, autoimmune encephalomyelitis, and collagen arthritis. The L3T4 antigen in the mouse is analogous to the human Leu-3/T4 antigen expressed on helper T lymphocytes, because they both participate in the T cell response to class II major histocompatibility complex (MHC) antigens. Class II MHC genes and I-A antigens mediate murine experimental autoimmune myasthenia gravis (EAMG) induced by acetylcholine receptor (AChR) autoimmunity. We studied the efficacy of mAb GK1.5 as an immunotherapeutic agent for murine EAMG. Therapy with mAb GK1.5 not only suppressed established autoimmunity to AChR but also prevented loss of muscle AChR in mice with EAMG. Moreover, permanent remission of clinical muscle weakness was induced if mAb GK1.5 therapy was initiated after the onset of clinical disease. Because the function of the Leu-3/T4 determinant on human helper T lymphocytes is analogous to the murine L3T4 determinant, use of antibody to the Leu-3/T4 determinant as an immunotherapeutic agent may provide a way to control the progression of human MG.

Original languageEnglish (US)
Pages (from-to)2437-2440
Number of pages4
JournalJournal of Immunology
Volume136
Issue number7
StatePublished - 1986
Externally publishedYes

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Myasthenia Gravis
Immunotherapy
Cholinergic Receptors
T Lymphocyte Differentiation Antigens
Helper-Inducer T-Lymphocytes
Histocompatibility Antigens Class II
Major Histocompatibility Complex
Autoimmunity
Encephalomyelitis
Experimental Arthritis
Muscle Weakness
Glycoproteins
Therapeutics
T-Lymphocytes
Antigens
Muscles
monoclonal antibody GK1.5
Antibodies
Genes

ASJC Scopus subject areas

  • Immunology

Cite this

Christadoss, P., & Dauphinee, M. J. (1986). Immunotherapy for myasthenia gravis: A murine model. Journal of Immunology, 136(7), 2437-2440.

Immunotherapy for myasthenia gravis : A murine model. / Christadoss, P.; Dauphinee, M. J.

In: Journal of Immunology, Vol. 136, No. 7, 1986, p. 2437-2440.

Research output: Contribution to journalArticle

Christadoss, P & Dauphinee, MJ 1986, 'Immunotherapy for myasthenia gravis: A murine model', Journal of Immunology, vol. 136, no. 7, pp. 2437-2440.
Christadoss P, Dauphinee MJ. Immunotherapy for myasthenia gravis: A murine model. Journal of Immunology. 1986;136(7):2437-2440.
Christadoss, P. ; Dauphinee, M. J. / Immunotherapy for myasthenia gravis : A murine model. In: Journal of Immunology. 1986 ; Vol. 136, No. 7. pp. 2437-2440.
@article{3a3c740043694864a7541fa1b16324e1,
title = "Immunotherapy for myasthenia gravis: A murine model",
abstract = "In vivo therapy with monoclonal antibody (mAb) GK1.5, which recognizes a glycoprotein antigen designated L3T4 on murine helper T lymphocytes, either prevented or suppressed the development of murine lupus, autoimmune encephalomyelitis, and collagen arthritis. The L3T4 antigen in the mouse is analogous to the human Leu-3/T4 antigen expressed on helper T lymphocytes, because they both participate in the T cell response to class II major histocompatibility complex (MHC) antigens. Class II MHC genes and I-A antigens mediate murine experimental autoimmune myasthenia gravis (EAMG) induced by acetylcholine receptor (AChR) autoimmunity. We studied the efficacy of mAb GK1.5 as an immunotherapeutic agent for murine EAMG. Therapy with mAb GK1.5 not only suppressed established autoimmunity to AChR but also prevented loss of muscle AChR in mice with EAMG. Moreover, permanent remission of clinical muscle weakness was induced if mAb GK1.5 therapy was initiated after the onset of clinical disease. Because the function of the Leu-3/T4 determinant on human helper T lymphocytes is analogous to the murine L3T4 determinant, use of antibody to the Leu-3/T4 determinant as an immunotherapeutic agent may provide a way to control the progression of human MG.",
author = "P. Christadoss and Dauphinee, {M. J.}",
year = "1986",
language = "English (US)",
volume = "136",
pages = "2437--2440",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Immunotherapy for myasthenia gravis

T2 - A murine model

AU - Christadoss, P.

AU - Dauphinee, M. J.

PY - 1986

Y1 - 1986

N2 - In vivo therapy with monoclonal antibody (mAb) GK1.5, which recognizes a glycoprotein antigen designated L3T4 on murine helper T lymphocytes, either prevented or suppressed the development of murine lupus, autoimmune encephalomyelitis, and collagen arthritis. The L3T4 antigen in the mouse is analogous to the human Leu-3/T4 antigen expressed on helper T lymphocytes, because they both participate in the T cell response to class II major histocompatibility complex (MHC) antigens. Class II MHC genes and I-A antigens mediate murine experimental autoimmune myasthenia gravis (EAMG) induced by acetylcholine receptor (AChR) autoimmunity. We studied the efficacy of mAb GK1.5 as an immunotherapeutic agent for murine EAMG. Therapy with mAb GK1.5 not only suppressed established autoimmunity to AChR but also prevented loss of muscle AChR in mice with EAMG. Moreover, permanent remission of clinical muscle weakness was induced if mAb GK1.5 therapy was initiated after the onset of clinical disease. Because the function of the Leu-3/T4 determinant on human helper T lymphocytes is analogous to the murine L3T4 determinant, use of antibody to the Leu-3/T4 determinant as an immunotherapeutic agent may provide a way to control the progression of human MG.

AB - In vivo therapy with monoclonal antibody (mAb) GK1.5, which recognizes a glycoprotein antigen designated L3T4 on murine helper T lymphocytes, either prevented or suppressed the development of murine lupus, autoimmune encephalomyelitis, and collagen arthritis. The L3T4 antigen in the mouse is analogous to the human Leu-3/T4 antigen expressed on helper T lymphocytes, because they both participate in the T cell response to class II major histocompatibility complex (MHC) antigens. Class II MHC genes and I-A antigens mediate murine experimental autoimmune myasthenia gravis (EAMG) induced by acetylcholine receptor (AChR) autoimmunity. We studied the efficacy of mAb GK1.5 as an immunotherapeutic agent for murine EAMG. Therapy with mAb GK1.5 not only suppressed established autoimmunity to AChR but also prevented loss of muscle AChR in mice with EAMG. Moreover, permanent remission of clinical muscle weakness was induced if mAb GK1.5 therapy was initiated after the onset of clinical disease. Because the function of the Leu-3/T4 determinant on human helper T lymphocytes is analogous to the murine L3T4 determinant, use of antibody to the Leu-3/T4 determinant as an immunotherapeutic agent may provide a way to control the progression of human MG.

UR - http://www.scopus.com/inward/record.url?scp=0022627666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022627666&partnerID=8YFLogxK

M3 - Article

C2 - 2419435

AN - SCOPUS:0022627666

VL - 136

SP - 2437

EP - 2440

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -